AMENDMENTS TO THE CLAIMS

1. (original) A chemical compound represented by general formula (I)

or a pharmaceutically acceptable salt thereof, wherein

 R^o , R^m and R^p independently of each other represent hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy; with the proviso that not all three of R^o , R^m and R^p represent hydrogen;

R², R³, R⁴ and R⁵ independently of each other represent hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;

with the proviso that the compound is not

N-(3-Trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea.

2. (original) The compound of claim 1, wherein

R° represents hydrogen;

Rm represents hydrogen; and

R^p represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

3. (original) The compound of claim 1, wherein

R° represents hydrogen;

R^p represents hydrogen; and

R^m represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

4. (currently amended) The compound of claim 1 any one of claims 1-3, wherein R^3 , R^4 and R^5 represent hydrogen; and

 R^2 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

- 5. (currently amended) The compound of claim 1 any one of claims 1-3, wherein R^2 , R^4 and R^5 represent hydrogen; and
- $\ensuremath{R^3}$ represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
- 6. (currently amended) The compound of claim 1 any one of claims 1-3, wherein

R², R³ and R⁵ represent hydrogen; and

R⁴ represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

7. (currently amended) The compound of claim 1 any one of claims 1-3, wherein

R2 and R5 represent hydrogen; and

R³ and R⁴ independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

- 8. (currently amended) The compound of claim 1 any one of claims 1–3, wherein R^2 and R^4 represent hydrogen; and R^3 and R^5 independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
- 9. (original) The compound of claim 1, being

 N-(4-Chloro-3-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

 N-(3-Trifluoromethyl-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

 N-(4-Chloro-3-trifluoromethyl-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

 N-(3,5-Dichloro-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

 N-(3,5-Difluoro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

 N-(3,5-Difluoro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

 N-(3-Trifluoromethyl-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-5-yl]-urea;

 N-(4-Chloro-3-trifluoromethyl-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

 N-(3,5-Dichloro-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

N- (4-Fluoro-3-trifluoromethyl-phenyl)-*N*′-[3-(1*H*-tetrazol-5-yl)-4′-trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(4-Fluoro-3-trifluoromethyl-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(4-Fluoro-3-trifluoromethyl-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(2-Trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea; N-(2-Trifluoromethyl-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(2-Bromo-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea; N-(2-Bromo-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(2-Bromo-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

- I. N-(2-Bromo-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- II. N-(2-Fluoro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- III. N-(2-Fluoro-phenyl)-N'-[4'-chloro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- IV. N-(2-Fluoro-phenyl)-N'-[4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea; N-(2-Fluoro-phenyl)-N'-[4'-methyl-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- V. N-(2-Chloro-phenyl)-N'-[4'-methyl-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

```
N-(2-Bromo-phenyl)-N'-[4'-methyl-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;
```

$$N$$
-(2-Trifluoromethyl-phenyl)- N' -[4'-methyl-3-(1 H -tetrazol-5-yl)-biphenyl-4-yl]-urea;

$$N$$
-(2-Chloro-phenyl)- N' -[3-(1 H -tetrazol-5-yl)- $4'$ -trifluoromethyl-biphenyl-4-yl]-urea;

$$N-(2-\text{Chloro-phenyl})-N'-[4'-\text{chloro-}3-(1H-\text{tetrazol-}5-\text{yl})-\text{biphenyl-}4-\text{yl}]-\text{urea};$$

$$N$$
-(3,5-Difluoro-phenyl)- N '-[3-(1 H -tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;

$$N$$
-(3,5-Dichloro-phenyl)- N '-[3-(1 H -tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;

$$N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-henyl$$

urea;

yl]-urea;

$$N$$
-(3,5-Difluoro-phenyl)- N' -[3-(1 H -tetrazol-5-yl)-3 $'$ -trifluoromethyl-biphenyl-4-yl]-urea;

$$N$$
-(3,5-Dichloro-phenyl)- N' -[3-(1 H -tetrazol-5-yl)-3 $'$ -trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Difluoro-phenyl)-N'-[4'-methoxy-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[4'-methoxy-3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-urea;

N-(3-Bromo-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

N-(4-Chloro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

N- (4-Fluoro-3-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-

or a pharmaceutically acceptable salt thereof.

10. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to <u>claim lany of claims 1-9</u>, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

- or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to the blockade of chloride channels, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. The use of a compound according to any one of claims 1–9, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to the blockade of chloride channels.
- 12. (currently amended) The <u>methoduse</u> according to claim 11, wherein the disease, disorder or condition responsive to the blockade of chloride channels is a bone metabolic disease, an osteoclast related bone disease, or a disease, disorder or condition that is responsive to inhibition of angiogenesis.
- 13. (cancelled) A method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or

comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-9, or a pharmaceutically acceptable salt thereof.